s ystolic h eart failure treatment with the i f inhibitor ivabradine t rial
DESCRIPTION
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. Borer JS, et al. Am J Cardiol . 2013. 2014;113(3):497-503. - PowerPoint PPT PresentationTRANSCRIPT
SSystolic ystolic HHeart failure treatment witheart failure treatment with
the the IIff inhibitor ivabradine inhibitor ivabradine TTrialrial
Efficacy and safety of ivabradine in patients Efficacy and safety of ivabradine in patients with severe chronic systolic heart with severe chronic systolic heart
failure/left ventricular dysfunction in the failure/left ventricular dysfunction in the SHIFT trialSHIFT trial
Efficacy and safety of ivabradine in patients Efficacy and safety of ivabradine in patients with severe chronic systolic heart with severe chronic systolic heart
failure/left ventricular dysfunction in the failure/left ventricular dysfunction in the SHIFT trialSHIFT trial
www.shift-study.comBorer JS, et al. Am J Cardiol. 2013. 2014;113(3):497-503
Patients with heart rate ≥70 bpm
HR P for interaction
Primary composite endpoint
Less severe heart failure (NYHA II or III and LVEF>20%)
0.82
0.854Severe heart failure (NYHA IV and/or LVEF≤20%)
0.84
Cardiovascular deathLess severe heart failure 0.94
0.264Severe heart failure 0.78
Hospitalisation for worsening heart failure
Less severe heart failure 0.73 0.419
Severe heart failure 0.83
Efficacy of ivabradine in patients according to heart failure severity
Ivabradine can be safely used in severe heart failure, and may improve clinical outcomes, independently of disease severity
www.shift-study.comBorer JS, et al. Am J Cardiol. 2013. 2014;113(3):497-503
0
10
20
30
40
50
60
0 1 2 3
inci
denc
e of
pri
mar
y co
mpo
stie
endp
oint
(%)
Time (years)
Ivabradine, Less severe
Ivabradine, Severe
Placebo, Less severe
Placebo, Severe
Efficacy of ivabradine in patients according to heart failure severity
www.shift-study.comBorer JS, et al. Am J Cardiol. 2013. 2014;113(3):497-503